Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349423 | 0.85 | PDK4 (0.41) | HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL13315683 | 0.80 | ALDH1A1 (0.42) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3556757 | 0.76 | MAPK1 (0.40) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3556756 | 0.76 | MAPK1 (0.40) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3560689 | 0.74 | ALDH1A1 (0.46) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3560690 | 0.74 | ALDH1A1 (0.46) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3560685 | 0.74 | ALDH1A1 (0.46) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3132153 | 0.73 | HSD17B10 (0.47) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3560372 | 0.73 | HSD17B10 (0.47) | HSD17B10CA12CA9KMT2AMEN1 | |
| SCHEMBL3564500 | 0.73 | HSD17B10 (0.47) | HSD17B10CA12CA9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732612-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | disclosed |
| EP-1675852-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-18 | — | — | EP | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-20060052359-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-09 | — | — | US | disclosed |
| US-20050101588-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | GRANT EUGENE B III (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052359-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | NQO2, NQO1, REN | HSD17B10 3364/4885CA12 3691/4885CA9 2020/4885 |
| US-20050101588-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | NQO2, NQO1, REN | HSD17B10 3364/4885CA12 3691/4885CA9 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.